Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease | Zendy

Sahar Fathallah-Shaykh | Zendy; Dorota Drożdż | Zendy; Joseph T. Flynn | Zendy; Randall Jenkins | Zendy; Katherine WesselingPerry | Zendy; Sarah J. Swartz | Zendy; Craig S. Wong | Zendy; Beverly Accomando | Zendy; Gerald F. Cox | Zendy; Bradley A. Warady | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease

Author(s) -

Sahar Fathallah-Shaykh,

Dorota Drożdż,

Joseph T. Flynn,

Randall Jenkins,

Katherine WesselingPerry,

Sarah J. Swartz,

Craig S. Wong,

Beverly Accomando,

Gerald F. Cox,

Bradley A. Warady

Publication year - 2017

Publication title -

pediatric nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.831

H-Index - 107

eISSN - 1432-198X

pISSN - 0931-041X

DOI - 10.1007/s00467-017-3787-0

Subject(s) - medicine , hyperphosphatemia , sevelamer , placebo , kidney disease , discontinuation , dialysis , phosphate binder , adverse effect , nephrology , gastroenterology , alternative medicine , pathology

Treatment for hyperphosphatemia in chronic kidney disease (CKD) involves dietary control of phosphorus intake, dialysis, and treatment with oral phosphate binders, none of which were approved by the Federal Food and Drug Administration in pediatric patients at the time of this study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research